NCT01859767View on ClinicalTrials.gov

Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

April 30, 2015

Conditions

Alzheimer's Disease

Interventions

DRUG

[123I]MNI-672 SPECT

Subjects will be dosed by intravenous injection to a target dose of 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) I-123 MNI-672 prior to the SPECT scan.

Trial Locations (1)

06510

Molecular NeuroImaging, LLC, New Haven